SCH CD-EPINEPHRINE DELIVERY

Illinois General Assembly - Full Text of HB4219

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of HB4219

Home

Legislation

Full Text

HB4219 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Printer Friendly Version

Introduced

Open PDF

104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026
HB4219

Introduced 1/14/2026, by Rep. Martha Deuter

SYNOPSIS AS INTRODUCED:

105 ILCS 5/22-30

Amends the School Code. Changes the term "epinephrine injector" to
"epinephrine delivery system" in a provision regarding the
self-administration, self-carry, and administration of epinephrine
delivery systems. Defines "epinephrine delivery system" as any form of
epinephrine that is approved by the United States Food and Drug
Administration and that is used to administer epinephrine into the human
body to prevent or treat a life-threatening allergic reaction. Requires
the entity or individual conducting the training curriculum to recognize
and respond to anaphylaxis to issue a certificate to each person who
successfully completes the anaphylaxis training program. Allows the
anaphylaxis training to include the proper techniques for administering
non-injector epinephrine options. Effective July 30, 2026.
LRB104 15974 LNS 29217 b

A BILL FOR

HB4219
LRB104 15974 LNS 29217 b
1

AN ACT concerning education.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The School Code is amended by changing Section
5
22-30 as follows:

6

(105 ILCS 5/22-30)
7

Sec. 22-30.
Self-administration and self-carry of asthma
8
medication and epinephrine
delivery systems

injectors
;
9
administration of undesignated epinephrine
delivery systems

10
injectors
; administration of an opioid antagonist;
11
administration of undesignated asthma medication; supply of
12
undesignated oxygen tanks; asthma episode emergency response
13
protocol.
14

(a) For the purpose of this Section only, the following
15
terms shall have the meanings set forth below:
16

"Asthma action plan" means a written plan developed with a
17
pupil's medical provider to help control the pupil's asthma.
18
The goal of an asthma action plan is to reduce or prevent
19
flare-ups and emergency department visits through day-to-day
20
management and to serve as a student-specific document to be
21
referenced in the event of an asthma episode.
22

"Asthma episode emergency response protocol" means a
23
procedure to provide assistance to a pupil experiencing

HB4219
- 2 -
LRB104 15974 LNS 29217 b
1
symptoms of wheezing, coughing, shortness of breath, chest
2
tightness, or breathing difficulty.
3

"Epinephrine injector" includes an auto-injector approved
4
by the United States Food and Drug Administration for the
5
administration of epinephrine and a pre-filled syringe
6
approved by the United States Food and Drug Administration and
7
used for the administration of epinephrine that contains a
8
pre-measured dose of epinephrine that is equivalent to the
9
dosages used in an auto-injector.
10

"Asthma medication" means quick-relief asthma medication,
11
including albuterol or other short-acting bronchodilators,
12
that is approved by the United States Food and Drug
13
Administration for the treatment of respiratory distress.
14
"Asthma medication" includes medication delivered through a
15
device, including a metered dose inhaler with a reusable or
16
disposable spacer or a nebulizer with a mouthpiece or mask.
17

"Epinephrine delivery system" means any form of
18
epinephrine that is approved by the United States Food and
19
Drug Administration, including any device that contains a dose
20
of epinephrine, and that is used to administer epinephrine
21
into the human body to prevent or treat a life-threatening
22
allergic reaction.

23

"Opioid antagonist" means a drug that binds to opioid
24
receptors and blocks or inhibits the effect of opioids acting
25
on those receptors, including, but not limited to, naloxone
26
hydrochloride or any other similarly acting drug approved by

HB4219
- 3 -
LRB104 15974 LNS 29217 b
1
the U.S. Food and Drug Administration.
2

"Respiratory distress" means the perceived or actual
3
presence of wheezing, coughing, shortness of breath, chest
4
tightness, breathing difficulty, or any other symptoms
5
consistent with asthma. Respiratory distress may be
6
categorized as "mild-to-moderate" or "severe".
7

"School nurse" means a registered nurse working in a
8
school with or without licensure endorsed in school nursing.
9

"Self-administration" means a pupil's discretionary use of
10
his or her prescribed asthma medication or epinephrine
11
delivery system

injector
.
12

"Self-carry" means a pupil's ability to carry his or her
13
prescribed asthma medication or epinephrine
delivery system

14
injector
.
15

"Standing protocol" may be issued by (i) a physician
16
licensed to practice medicine in all its branches, (ii) a
17
licensed physician assistant with prescriptive authority, or
18
(iii) a licensed advanced practice registered nurse with
19
prescriptive authority.
20

"Trained personnel" means any school employee or volunteer
21
personnel authorized in Sections 10-22.34, 10-22.34a, and
22
10-22.34b of this Code who has completed training under
23
subsection (g) of this Section to recognize and respond to
24
anaphylaxis, an opioid overdose, or respiratory distress.
25

"Undesignated asthma medication" means asthma medication
26
prescribed in the name of a school district, public school,

HB4219
- 4 -
LRB104 15974 LNS 29217 b
1
charter school, or nonpublic school.
2

"Undesignated epinephrine
delivery system

injector
" means
3
an epinephrine
delivery system

injector
prescribed in the name
4
of a school district, public school, charter school, or
5
nonpublic school.
6

(b) A school, whether public, charter, or nonpublic, must
7
permit the self-administration and self-carry of asthma
8
medication by a pupil with asthma or the self-administration
9
and self-carry of an epinephrine
delivery system

injector
by a
10
pupil, provided that:
11

(1) the parents or guardians of the pupil provide to
12

the school (i) written authorization from the parents or
13

guardians for (A) the self-administration and self-carry
14

of asthma medication or (B) the self-carry of asthma
15

medication or (ii) for (A) the self-administration and
16

self-carry of an epinephrine
delivery system

injector
or
17

(B) the self-carry of an epinephrine
delivery system

18

injector
, written authorization from the pupil's
19

physician, physician assistant, or advanced practice
20

registered nurse; and
21

(2) the parents or guardians of the pupil provide to
22

the school (i) the prescription label, which must contain
23

the name of the asthma medication, the prescribed dosage,
24

and the time at which or circumstances under which the
25

asthma medication is to be administered, or (ii) for the
26

self-administration or self-carry of an epinephrine

HB4219
- 5 -
LRB104 15974 LNS 29217 b
1

delivery system

injector
, a written statement from the
2

pupil's physician, physician assistant, or advanced
3

practice registered nurse containing the following
4

information:
5

(A) the name and purpose of the epinephrine
6

delivery system

injector
;
7

(B) the prescribed dosage; and
8

(C) the time or times at which or the special
9

circumstances under which the epinephrine
delivery
10

system

injector
is to be administered.
11
The information provided shall be kept on file in the office of
12
the school nurse or, in the absence of a school nurse, the
13
school's administrator.
14

(b-5) A school district, public school, charter school, or
15
nonpublic school may authorize the provision of a
16
student-specific or undesignated epinephrine
delivery system

17
injector
to a student or any personnel authorized under a
18
student's Individual Health Care Action Plan, allergy
19
emergency action plan, or plan pursuant to Section 504 of the
20
federal Rehabilitation Act of 1973 to administer an
21
epinephrine
delivery system

injector
to the student, that
22
meets the student's prescription on file.
23

(b-10) The school district, public school, charter school,
24
or nonpublic school may authorize a school nurse or trained
25
personnel to do the following: (i) provide an undesignated
26
epinephrine
delivery system

injector
to a student for

HB4219
- 6 -
LRB104 15974 LNS 29217 b
1
self-administration only or any personnel authorized under a
2
student's Individual Health Care Action Plan, allergy
3
emergency action plan, plan pursuant to Section 504 of the
4
federal Rehabilitation Act of 1973, or individualized
5
education program plan to administer to the student that meets
6
the student's prescription on file; (ii) administer an
7
undesignated epinephrine
delivery system

injector
that meets
8
the prescription on file to any student who has an Individual
9
Health Care Action Plan, allergy emergency action plan, plan
10
pursuant to Section 504 of the federal Rehabilitation Act of
11
1973, or individualized education program plan that authorizes
12
the use of an epinephrine
delivery system

injector
; (iii)
13
administer an undesignated epinephrine
delivery system

14
injector
to any person that the school nurse or trained
15
personnel in good faith believes is having an anaphylactic
16
reaction; (iv) administer an opioid antagonist to any person
17
that the school nurse or trained personnel in good faith
18
believes is having an opioid overdose; (v) provide
19
undesignated asthma medication to a student for
20
self-administration only or to any personnel authorized under
21
a student's Individual Health Care Action Plan or asthma
22
action plan, plan pursuant to Section 504 of the federal
23
Rehabilitation Act of 1973, or individualized education
24
program plan to administer to the student that meets the
25
student's prescription on file; (vi) administer undesignated
26
asthma medication that meets the prescription on file to any

HB4219
- 7 -
LRB104 15974 LNS 29217 b
1
student who has an Individual Health Care Action Plan or
2
asthma action plan, plan pursuant to Section 504 of the
3
federal Rehabilitation Act of 1973, or individualized
4
education program plan that authorizes the use of asthma
5
medication; and (vii) administer undesignated asthma
6
medication to any person that the school nurse or trained
7
personnel believes in good faith is having respiratory
8
distress.
9

(c) The school district, public school, charter school, or
10
nonpublic school must inform the parents or guardians of the
11
pupil, in writing, that the school district, public school,
12
charter school, or nonpublic school and its employees and
13
agents, including a physician, physician assistant, or
14
advanced practice registered nurse providing standing protocol
15
and a prescription for school epinephrine
delivery systems

16
injectors
, an opioid antagonist, or undesignated asthma
17
medication, are to incur no liability or professional
18
discipline, except for willful and wanton conduct, as a result
19
of any injury arising from the administration of asthma
20
medication, an epinephrine
delivery system

injector
, or an
21
opioid antagonist regardless of whether authorization was
22
given by the pupil's parents or guardians or by the pupil's
23
physician, physician assistant, or advanced practice
24
registered nurse. The parents or guardians of the pupil must
25
sign a statement acknowledging that the school district,
26
public school, charter school, or nonpublic school and its

HB4219
- 8 -
LRB104 15974 LNS 29217 b
1
employees and agents are to incur no liability, except for
2
willful and wanton conduct, as a result of any injury arising
3
from the administration of asthma medication, an epinephrine
4
delivery system

injector
, or an opioid antagonist regardless
5
of whether authorization was given by the pupil's parents or
6
guardians or by the pupil's physician, physician assistant, or
7
advanced practice registered nurse and that the parents or
8
guardians must indemnify and hold harmless the school
9
district, public school, charter school, or nonpublic school
10
and its employees and agents against any claims, except a
11
claim based on willful and wanton conduct, arising out of the
12
administration of asthma medication, an epinephrine
delivery
13
system

injector
, or an opioid antagonist regardless of whether
14
authorization was given by the pupil's parents or guardians or
15
by the pupil's physician, physician assistant, or advanced
16
practice registered nurse.
17

(c-5) When a school nurse or trained personnel administers
18
an undesignated epinephrine
delivery system

injector
to a
19
person whom the school nurse or trained personnel in good
20
faith believes is having an anaphylactic reaction, administers
21
an opioid antagonist to a person whom the school nurse or
22
trained personnel in good faith believes is having an opioid
23
overdose, or administers undesignated asthma medication to a
24
person whom the school nurse or trained personnel in good
25
faith believes is having respiratory distress, notwithstanding
26
the lack of notice to the parents or guardians of the pupil or

HB4219
- 9 -
LRB104 15974 LNS 29217 b
1
the absence of the parents or guardians signed statement
2
acknowledging no liability, except for willful and wanton
3
conduct, the school district, public school, charter school,
4
or nonpublic school and its employees and agents, and a
5
physician, a physician assistant, or an advanced practice
6
registered nurse providing standing protocol and a
7
prescription for undesignated epinephrine
delivery systems

8
injectors
, an opioid antagonist, or undesignated asthma
9
medication, are to incur no liability or professional
10
discipline, except for willful and wanton conduct, as a result
11
of any injury arising from the use of an undesignated
12
epinephrine
delivery system

injector
, the use of an opioid
13
antagonist, or the use of undesignated asthma medication,
14
regardless of whether authorization was given by the pupil's
15
parents or guardians or by the pupil's physician, physician
16
assistant, or advanced practice registered nurse.
17

(d) The permission for self-administration and self-carry
18
of asthma medication or the self-administration and self-carry
19
of an epinephrine
delivery system

injector
is effective for
20
the school year for which it is granted and shall be renewed
21
each subsequent school year upon fulfillment of the
22
requirements of this Section.
23

(e) Provided that the requirements of this Section are
24
fulfilled, a pupil with asthma may self-administer and
25
self-carry his or her asthma medication or a pupil may
26
self-administer and self-carry an epinephrine
delivery system

HB4219
- 10 -
LRB104 15974 LNS 29217 b
1
injector
(i) while in school, (ii) while at a school-sponsored
2
activity, (iii) while under the supervision of school
3
personnel, or (iv) before or after normal school activities,
4
such as while in before-school or after-school care on
5
school-operated property or while being transported on a
6
school bus.
7

(e-5) Provided that the requirements of this Section are
8
fulfilled, a school nurse or trained personnel may administer
9
an undesignated epinephrine
delivery system

injector
to any
10
person whom the school nurse or trained personnel in good
11
faith believes to be having an anaphylactic reaction (i) while
12
in school, (ii) while at a school-sponsored activity, (iii)
13
while under the supervision of school personnel, or (iv)
14
before or after normal school activities, such as while in
15
before-school or after-school care on school-operated property
16
or while being transported on a school bus. A school nurse or
17
trained personnel may carry undesignated epinephrine
delivery
18
systems

injectors
on his or her person while in school or at a
19
school-sponsored activity.
20

(e-10) Provided that the requirements of this Section are
21
fulfilled, a school nurse or trained personnel may administer
22
an opioid antagonist to any person whom the school nurse or
23
trained personnel in good faith believes to be having an
24
opioid overdose (i) while in school, (ii) while at a
25
school-sponsored activity, (iii) while under the supervision
26
of school personnel, or (iv) before or after normal school

HB4219
- 11 -
LRB104 15974 LNS 29217 b
1
activities, such as while in before-school or after-school
2
care on school-operated property. A school nurse or trained
3
personnel may carry an opioid antagonist on his or her person
4
while in school or at a school-sponsored activity.
5

(e-15) If the requirements of this Section are met, a
6
school nurse or trained personnel may administer undesignated
7
asthma medication to any person whom the school nurse or
8
trained personnel in good faith believes to be experiencing
9
respiratory distress (i) while in school, (ii) while at a
10
school-sponsored activity, (iii) while under the supervision
11
of school personnel, or (iv) before or after normal school
12
activities, including before-school or after-school care on
13
school-operated property. A school nurse or trained personnel
14
may carry undesignated asthma medication on his or her person
15
while in school or at a school-sponsored activity.
16

(f) The school district, public school, charter school, or
17
nonpublic school may maintain a supply of undesignated
18
epinephrine
delivery systems

injectors
in any secure location
19
that is accessible before, during, and after school where an
20
allergic person is most at risk, including, but not limited
21
to, classrooms and lunchrooms. A physician, a physician
22
assistant who has prescriptive authority in accordance with
23
Section 7.5 of the Physician Assistant Practice Act of 1987,
24
or an advanced practice registered nurse who has prescriptive
25
authority in accordance with Section 65-40 of the Nurse
26
Practice Act may prescribe undesignated epinephrine
delivery

HB4219
- 12 -
LRB104 15974 LNS 29217 b
1
systems

injectors
in the name of the school district, public
2
school, charter school, or nonpublic school to be maintained
3
for use when necessary. Any supply of epinephrine
delivery
4
systems

injectors
shall be maintained in accordance with the
5
manufacturer's instructions.
6

The school district, public school, charter school, or
7
nonpublic school shall maintain a supply of an opioid
8
antagonist in any secure location where an individual may have
9
an opioid overdose, unless there is a shortage of opioid
10
antagonists, in which case the school district, public school,
11
charter school, or nonpublic school shall make a reasonable
12
effort to maintain a supply of an opioid antagonist. Unless
13
the school district, public school, charter school, or
14
nonpublic school is able to obtain opioid antagonists without
15
a prescription, a health care professional who has been
16
delegated prescriptive authority for opioid antagonists in
17
accordance with Section 5-23 of the Substance Use Disorder Act
18
shall prescribe opioid antagonists in the name of the school
19
district, public school, charter school, or nonpublic school,
20
to be maintained for use when necessary. Any supply of opioid
21
antagonists shall be maintained in accordance with the
22
manufacturer's instructions.
23

The school district, public school, charter school, or
24
nonpublic school may maintain a supply of asthma medication in
25
any secure location that is accessible before, during, or
26
after school where a person is most at risk, including, but not

HB4219
- 13 -
LRB104 15974 LNS 29217 b
1
limited to, a classroom or the nurse's office. A physician, a
2
physician assistant who has prescriptive authority under
3
Section 7.5 of the Physician Assistant Practice Act of 1987,
4
or an advanced practice registered nurse who has prescriptive
5
authority under Section 65-40 of the Nurse Practice Act may
6
prescribe undesignated asthma medication in the name of the
7
school district, public school, charter school, or nonpublic
8
school to be maintained for use when necessary. Any supply of
9
undesignated asthma medication must be maintained in
10
accordance with the manufacturer's instructions.
11

A school district that provides special educational
12
facilities for children with disabilities under Section
13
14-4.01 of this Code may maintain a supply of undesignated
14
oxygen tanks in any secure location that is accessible before,
15
during, and after school where a person with developmental
16
disabilities is most at risk, including, but not limited to,
17
classrooms and lunchrooms. A physician, a physician assistant
18
who has prescriptive authority in accordance with Section 7.5
19
of the Physician Assistant Practice Act of 1987, or an
20
advanced practice registered nurse who has prescriptive
21
authority in accordance with Section 65-40 of the Nurse
22
Practice Act may prescribe undesignated oxygen tanks in the
23
name of the school district that provides special educational
24
facilities for children with disabilities under Section
25
14-4.01 of this Code to be maintained for use when necessary.
26
Any supply of oxygen tanks shall be maintained in accordance

HB4219
- 14 -
LRB104 15974 LNS 29217 b
1
with the manufacturer's instructions and with the local fire
2
department's rules.
3

(f-3) Whichever entity initiates the process of obtaining
4
undesignated epinephrine
delivery systems

injectors
and
5
providing training to personnel for carrying and administering
6
undesignated epinephrine
delivery systems

injectors
shall pay
7
for the costs of the undesignated epinephrine
delivery systems

8
injectors
.
9

(f-5) Upon any administration of an epinephrine
delivery
10
system

injector
, a school district, public school, charter
11
school, or nonpublic school must immediately activate the EMS
12
system and notify the student's parent, guardian, or emergency
13
contact, if known.
14

Upon any administration of an opioid antagonist, a school
15
district, public school, charter school, or nonpublic school
16
must immediately activate the EMS system and notify the
17
student's parent, guardian, or emergency contact, if known.
18

(f-10) Within 24 hours of the administration of an
19
undesignated epinephrine
delivery system

injector
, a school
20
district, public school, charter school, or nonpublic school
21
must notify the physician, physician assistant, or advanced
22
practice registered nurse who provided the standing protocol
23
and a prescription for the undesignated epinephrine
delivery
24
system

injector
of its use.
25

Within 24 hours after the administration of an opioid
26
antagonist, a school district, public school, charter school,

HB4219
- 15 -
LRB104 15974 LNS 29217 b
1
or nonpublic school must notify the health care professional
2
who provided the prescription for the opioid antagonist of its
3
use.
4

Within 24 hours after the administration of undesignated
5
asthma medication, a school district, public school, charter
6
school, or nonpublic school must notify the student's parent
7
or guardian or emergency contact, if known, and the physician,
8
physician assistant, or advanced practice registered nurse who
9
provided the standing protocol and a prescription for the
10
undesignated asthma medication of its use. The district or
11
school must follow up with the school nurse, if available, and
12
may, with the consent of the child's parent or guardian,
13
notify the child's health care provider of record, as
14
determined under this Section, of its use.
15

(g) Prior to the administration of an undesignated
16
epinephrine
delivery system

injector
, trained personnel must
17
submit to the school's administration proof of completion of a
18
training curriculum to recognize and respond to anaphylaxis
19
that meets the requirements of subsection (h) of this Section.
20
Training must be completed annually. The school district,
21
public school, charter school, or nonpublic school must
22
maintain records related to the training curriculum and
23
trained personnel.
24

Prior to the administration of an opioid antagonist,
25
trained personnel must submit to the school's administration
26
proof of completion of a training curriculum to recognize and

HB4219
- 16 -
LRB104 15974 LNS 29217 b
1
respond to an opioid overdose, which curriculum must meet the
2
requirements of subsection (h-5) of this Section. The school
3
district, public school, charter school, or nonpublic school
4
must maintain records relating to the training curriculum and
5
the trained personnel.
6

Prior to the administration of undesignated asthma
7
medication, trained personnel must submit to the school's
8
administration proof of completion of a training curriculum to
9
recognize and respond to respiratory distress, which must meet
10
the requirements of subsection (h-10) of this Section.
11
Training must be completed annually, and the school district,
12
public school, charter school, or nonpublic school must
13
maintain records relating to the training curriculum and the
14
trained personnel.
15

(h) A training curriculum to recognize and respond to
16
anaphylaxis, including the administration of an undesignated
17
epinephrine
delivery system

injector
, may be conducted online
18
or in person.
The entity or individual conducting the training
19
shall issue a certificate to each person who successfully
20
completes the anaphylaxis training program.

21

Training shall include, but is not limited to:
22

(1) how to recognize signs and symptoms of an allergic
23

reaction, including anaphylaxis;
24

(2) how to administer an epinephrine
delivery system

25

injector
; and
26

(3) a test demonstrating competency of the knowledge

HB4219
- 17 -
LRB104 15974 LNS 29217 b
1

required to recognize anaphylaxis and administer an
2

epinephrine
delivery system

injector
.
3

Training may also include, but is not limited to:
4

(A) a review of high-risk areas within a school and
5

its related facilities;
6

(B) steps to take to prevent exposure to allergens;
7

(C) emergency follow-up procedures, including the
8

importance of calling 9-1-1 or, if 9-1-1 is not available,
9

other local emergency medical services;
10

(D) how to respond to a student with a known allergy,
11

as well as a student with a previously unknown allergy;
12

(D-5) the proper techniques for administering
13

non-injector epinephrine options;

14

(E) other criteria as determined in rules adopted
15

pursuant to this Section; and
16

(F) any policy developed by the State Board of
17

Education under Section 2-3.190.
18

In consultation with statewide professional organizations
19
representing physicians licensed to practice medicine in all
20
of its branches, registered nurses, and school nurses, the
21
State Board of Education shall make available resource
22
materials consistent with criteria in this subsection (h) for
23
educating trained personnel to recognize and respond to
24
anaphylaxis. The State Board may take into consideration the
25
curriculum on this subject developed by other states, as well
26
as any other curricular materials suggested by medical experts

HB4219
- 18 -
LRB104 15974 LNS 29217 b
1
and other groups that work on life-threatening allergy issues.
2
The State Board is not required to create new resource
3
materials. The State Board shall make these resource materials
4
available on its Internet website.
5

(h-5) A training curriculum to recognize and respond to an
6
opioid overdose, including the administration of an opioid
7
antagonist, may be conducted online or in person. The training
8
must comply with any training requirements under Section 5-23
9
of the Substance Use Disorder Act and the corresponding rules.
10
It must include, but is not limited to:
11

(1) how to recognize symptoms of an opioid overdose;
12

(2) information on drug overdose prevention and
13

recognition;
14

(3) how to perform rescue breathing and resuscitation;
15

(4) how to respond to an emergency involving an opioid
16

overdose;
17

(5) opioid antagonist dosage and administration;
18

(6) the importance of calling 9-1-1 or, if 9-1-1 is
19

not available, other local emergency medical services;
20

(7) care for the overdose victim after administration
21

of the overdose antagonist;
22

(8) a test demonstrating competency of the knowledge
23

required to recognize an opioid overdose and administer a
24

dose of an opioid antagonist; and
25

(9) other criteria as determined in rules adopted
26

pursuant to this Section.

HB4219
- 19 -
LRB104 15974 LNS 29217 b
1

(h-10) A training curriculum to recognize and respond to
2
respiratory distress, including the administration of
3
undesignated asthma medication, may be conducted online or in
4
person. The training must include, but is not limited to:
5

(1) how to recognize symptoms of respiratory distress
6

and how to distinguish respiratory distress from
7

anaphylaxis;
8

(2) how to respond to an emergency involving
9

respiratory distress;
10

(3) asthma medication dosage and administration;
11

(4) the importance of calling 9-1-1 or, if 9-1-1 is
12

not available, other local emergency medical services;
13

(5) a test demonstrating competency of the knowledge
14

required to recognize respiratory distress and administer
15

asthma medication; and
16

(6) other criteria as determined in rules adopted
17

under this Section.
18

(i) Within 3 days after the administration of an
19
undesignated epinephrine
delivery system

injector
by a school
20
nurse, trained personnel, or a student at a school or
21
school-sponsored activity, the school must report to the State
22
Board of Education in a form and manner prescribed by the State
23
Board the following information:
24

(1) age and type of person receiving epinephrine
25

(student, staff, visitor);
26

(2) any previously known diagnosis of a severe

HB4219
- 20 -
LRB104 15974 LNS 29217 b
1

allergy;
2

(3) trigger that precipitated allergic episode;
3

(4) location where symptoms developed;
4

(5) number of doses administered;
5

(6) type of person administering epinephrine (school
6

nurse, trained personnel, student); and
7

(7) any other information required by the State Board.
8

If a school district, public school, charter school, or
9
nonpublic school maintains or has an independent contractor
10
providing transportation to students who maintains a supply of
11
undesignated epinephrine
delivery systems

injectors
, then the
12
school district, public school, charter school, or nonpublic
13
school must report that information to the State Board of
14
Education upon adoption or change of the policy of the school
15
district, public school, charter school, nonpublic school, or
16
independent contractor, in a manner as prescribed by the State
17
Board. The report must include the number of undesignated
18
epinephrine
delivery systems

injectors
in supply.
19

(i-5) Within 3 days after the administration of an opioid
20
antagonist by a school nurse or trained personnel, the school
21
must report to the State Board of Education, in a form and
22
manner prescribed by the State Board, the following
23
information:
24

(1) the age and type of person receiving the opioid
25

antagonist (student, staff, or visitor);
26

(2) the location where symptoms developed;

HB4219
- 21 -
LRB104 15974 LNS 29217 b
1

(3) the type of person administering the opioid
2

antagonist (school nurse or trained personnel); and
3

(4) any other information required by the State Board.
4

(i-10) Within 3 days after the administration of
5
undesignated asthma medication by a school nurse, trained
6
personnel, or a student at a school or school-sponsored
7
activity, the school must report to the State Board of
8
Education, on a form and in a manner prescribed by the State
9
Board of Education, the following information:
10

(1) the age and type of person receiving the asthma
11

medication (student, staff, or visitor);
12

(2) any previously known diagnosis of asthma for the
13

person;
14

(3) the trigger that precipitated respiratory
15

distress, if identifiable;
16

(4) the location of where the symptoms developed;
17

(5) the number of doses administered;
18

(6) the type of person administering the asthma
19

medication (school nurse, trained personnel, or student);
20

(7) the outcome of the asthma medication
21

administration; and
22

(8) any other information required by the State Board.
23

(j) By October 1, 2015 and every year thereafter, the
24
State Board of Education shall submit a report to the General
25
Assembly identifying the frequency and circumstances of
26
undesignated epinephrine and undesignated asthma medication

HB4219
- 22 -
LRB104 15974 LNS 29217 b
1
administration during the preceding academic year. Beginning
2
with the 2017 report, the report shall also contain
3
information on which school districts, public schools, charter
4
schools, and nonpublic schools maintain or have independent
5
contractors providing transportation to students who maintain
6
a supply of undesignated epinephrine
delivery systems

7
injectors
. This report shall be published on the State Board's
8
Internet website on the date the report is delivered to the
9
General Assembly.
10

(j-5) Annually, each school district, public school,
11
charter school, or nonpublic school shall request an asthma
12
action plan from the parents or guardians of a pupil with
13
asthma. If provided, the asthma action plan must be kept on
14
file in the office of the school nurse or, in the absence of a
15
school nurse, the school administrator. Copies of the asthma
16
action plan may be distributed to appropriate school staff who
17
interact with the pupil on a regular basis, and, if
18
applicable, may be attached to the pupil's federal Section 504
19
plan or individualized education program plan.
20

(j-10) To assist schools with emergency response
21
procedures for asthma, the State Board of Education, in
22
consultation with statewide professional organizations with
23
expertise in asthma management and a statewide organization
24
representing school administrators, shall develop a model
25
asthma episode emergency response protocol before September 1,
26
2016. Each school district, charter school, and nonpublic

HB4219
- 23 -
LRB104 15974 LNS 29217 b
1
school shall adopt an asthma episode emergency response
2
protocol before January 1, 2017 that includes all of the
3
components of the State Board's model protocol.
4

(j-15) (Blank).
5

(j-20) On or before October 1, 2016 and every year
6
thereafter, the State Board of Education shall submit a report
7
to the General Assembly and the Department of Public Health
8
identifying the frequency and circumstances of opioid
9
antagonist administration during the preceding academic year.
10
This report shall be published on the State Board's Internet
11
website on the date the report is delivered to the General
12
Assembly.
13

(k) The State Board of Education may adopt rules necessary
14
to implement this Section.
15

(l) Nothing in this Section shall limit the amount of
16
epinephrine
delivery systems

injectors
that any type of school
17
or student may carry or maintain a supply of.
18
(Source: P.A. 102-413, eff. 8-20-21; 102-813, eff. 5-13-22;
19
103-175, eff. 6-30-23; 103-196, eff. 1-1-24; 103-348, eff.
20
1-1-24; 103-542, eff. 7-1-24 (see Section 905 of P.A. 103-563
21
for effective date of P.A. 103-542); 103-605, eff. 7-1-24.)

22

Section 99.
Effective date.
This Act takes effect July 30,
23
2026.

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn